Companies › Eisai
14 active drug programs in 37 registered trials: 13 Phase 1, 13 Phase 2, 7 Phase 3, 4 Phase 4; Oncology, Neurology, Immunology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Filgotinib Maleate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 4 | Ulcerative Colitis | Nov 2027 |
| Lecanemab (BAN2401) Amyloid-beta A4 protein inhibitor | APP | Phase 3 | Early Alzheimer's Disease; Preclinical Alzheimer's Disease; Alzheimer's Disease; Alzheimer's Disease(AD) … | Dec 2026 |
| Everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Renal Cell Carcinoma | Mar 2027 |
| E2086 | – | Phase 2 | Narcolepsy; Healthy Volunteers | Nov 2026 |
| E2814 Anti-tau monoclonal antibody | – | Phase 2 | Alzheimer's Disease; Alzheimers Disease | Dec 2026 |
| Perampanel Glutamate receptor ionotropic AMPA antagonist | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 2 | Pediatric Epileptic Syndrome; Depressive Disorder; Depression; Depressive Disorder, Major | Apr 2027 |
| E6742 | – | Phase 2 | Systemic Lupus Erythematosus | Aug 2028 |
| E7386 | – | Phase 1 | Advanced Neoplasms; Endometrial Neoplasms | Mar 2027 |
| E7386 | – | Phase 1 | Solid Neoplasms | Mar 2027 |
| Eribulin (E7389) Tubulin inhibitor | Tubulin | Phase 1 | Solid Tumor; Solid Neoplasms; Breast Neoplasms; Breast Cancer Stage IV … | Mar 2027 |
| H3B-6545 Estrogen receptor degrader (PROTAC) | – | Phase 1 | Receptors, Estrogen | Mar 2027 |
| E1018 | – | Phase 1 | Malaria | Jul 2027 |
| E-7090 (E7090) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Hepatic Impairment | Aug 2027 |
| Farletuzumab Folate receptor alpha inhibitor | FOLR1 | Phase 1 | Solid Tumor | Aug 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07034222 | Lecanemab (BAN2401) | Phase 4 | Alzheimer's Disease(AD) | Neurology | Jan 2026 |
| NCT06530732 | Lecanemab (BAN2401) | Phase 3 | Alzheimer's Disease | Neurology | Jun 2026 |
| NCT07766369 | E2086 | Phase 1 | Healthy Volunteers | Other | Nov 2026 |
| NCT06602258 | Lecanemab (BAN2401) | Phase 2 | Alzheimer's Disease | Neurology | Dec 2026 |
| NCT06602258 | E2814 | Phase 2 | Alzheimer's Disease | Neurology | Dec 2026 |
| NCT02623972 | Eribulin (E7389) | Phase 2 | Inflammatory Breast Cancer | Oncology | Dec 2026 |
| NCT03887455 | Lecanemab (BAN2401) | Phase 3 | Early Alzheimer's Disease | Neurology | Dec 2026 |
| NCT03973268 | Perampanel | Phase 1 | Depression | Psychiatry | Feb 2027 |
| NCT07493265 | E2086 | Phase 2 | Narcolepsy | Neurology | Feb 2027 |
| NCT04288089 | H3B-6545 | Phase 1 | Receptors, Estrogen | Oncology | Mar 2027 |
| NCT02811861 | Everolimus | Phase 3 | Renal Cell Carcinoma | Oncology | Mar 2027 |
| NCT03264664 | E7386 | Phase 1 | Advanced Neoplasms | Oncology | Mar 2027 |
| NCT04008797 | E7386 | Phase 1 | Endometrial Neoplasms | Oncology | Mar 2027 |
| NCT03833700 | E7386 | Phase 1 | Solid Neoplasms | Oncology | Mar 2027 |
| NCT03207672 | Eribulin (E7389) | Phase 1 | Solid Tumor | Oncology | Mar 2027 |
| NCT04078295 | Eribulin (E7389) | Phase 1 | Solid Neoplasms | Oncology | Mar 2027 |
| NCT04015141 | Perampanel | Phase 2 | Pediatric Epileptic Syndrome | Neurology | Apr 2027 |
| NCT06854042 | E1018 | Phase 1 | Malaria | Infectious disease | Jul 2027 |
| NCT07088263 | Eribulin (E7389) | Phase 3 | Breast Neoplasms | Oncology | Jul 2027 |
| NCT04271488 | E-7090 (E7090) | Phase 1 | Hepatic Impairment | Gastroenterology | Aug 2027 |
| NCT06964113 | Filgotinib Maleate | Phase 4 | Ulcerative Colitis | Immunology | Nov 2027 |
| NCT07604896 | Lecanemab (BAN2401) | Phase 4 | Alzheimer s Disease | Neurology | Dec 2027 |
| NCT01760005 | Lecanemab (BAN2401) | Phase 2 | Alzheimers Disease | Neurology | Apr 2028 |
| NCT05269394 | Lecanemab (BAN2401) | Phase 2 | Alzheimers Disease | Neurology | Apr 2028 |
| NCT01760005 | E2814 | Phase 2 | Alzheimers Disease | Neurology | Apr 2028 |
| NCT05269394 | E2814 | Phase 2 | Alzheimers Disease | Neurology | Apr 2028 |
| NCT04986579 | Eribulin (E7389) | Phase 2 | Metastatic Breast Cancer | Oncology | Jun 2028 |
| NCT07515014 | E6742 | Phase 2 | Systemic Lupus Erythematosus | Immunology | Aug 2028 |
| NCT04468659 | Lecanemab (BAN2401) | Phase 3 | Preclinical Alzheimer's Disease | Neurology | Dec 2028 |
| NCT06889688 | Eribulin (E7389) | Phase 3 | Breast Cancer Stage IV | Oncology | Dec 2028 |
| NCT07688460 | Lecanemab (BAN2401) | Phase 4 | Alzheimer Disease | Neurology | Mar 2029 |
| NCT07520760 | Eribulin (E7389) | Phase 2 | HER 2 Negative Breast Cancer | Oncology | Apr 2030 |
| NCT06384573 | Lecanemab (BAN2401) | Phase 3 | Alzheimer's Disease | Neurology | Jun 2030 |
| NCT04300556 | Farletuzumab | Phase 1 | Solid Tumor | Oncology | Aug 2030 |
| NCT06957431 | Eribulin (E7389) | Phase 1 | Advanced Leiomyosarcoma | Oncology | May 2031 |
| NCT05915013 | Perampanel | Phase 1 | Depressive Disorder, Major | Psychiatry | Dec 2032 |
| NCT05786066 | Perampanel | Phase 2 | Depressive Disorder | Psychiatry | Mar 2033 |
FKBP1A (1) APP (1) JAK1 (1) JAK2 (1) TYK2 (1) JAK3 (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) GRIA1 (1) FOLR1 (1) Tubulin (1)
AbbVie Pfizer Incyte Sun Pharmaceutical Industries Alfasigma Takeda LEO Pharma Eli Lilly Suzhou Zelgen Biopharmaceuticals Alnylam Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.